Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884019 | 0.92 | BCHE (0.39) | BCHEGNAI3GNAO1GNAI1DPP4 | |
| SCHEMBL23491300 | 0.83 | BCHE (0.41) | BCHEGNAI3GNAO1GNAI1DPP4 | |
| SCHEMBL22096796 | 0.83 | TSHR (0.37) | BCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL19779680 | 0.80 | BCHE (0.42) | BCHEGNAI3GNAO1GNAI1DPP4 | |
| SCHEMBL19865672 | 0.78 | BCHE (0.53) | BCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL19779848 | 0.78 | TSHR (0.33) | DPP4 | |
| SCHEMBL20621211 | 0.76 | ACKR3 (0.39) | — | |
| SCHEMBL19880561 | 0.76 | ACKR3 (0.39) | — | |
| SCHEMBL19780160 | 0.74 | DPP4 (0.37) | GNAI3GNAO1GNAI1DPP4 | |
| SCHEMBL19779643 | 0.74 | DPP4 (0.37) | GNAI3GNAO1GNAI1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875839-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190053-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | BCHE 2060/4885GNAI3 572/4885GNAO1 897/4885 |
| US-10875839-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | BCHE 2060/4885GNAI3 572/4885GNAO1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.